Clinical Data for Brigatinib/Brigatinib

Brigatinib/Brigatinib (Brigatinib) is a new tyrosine kinase inhibitor used to treat patients with ALK-positive non-small cell lung cancer (NSCLC). According to clinical study data, brigatinib has shown good efficacy and tolerability in the treatment of ALK-positive NSCLC. Here are some important clinical data:

1. Remarkable effect: In a multi-center, randomized, open-label clinical trial, researchers treated 129 patients with ALK-positive NSCLC with brigatinib. The results showed that 53% of patients in the brigatinib treatment group achieved partial response (PR), and some of them achieved complete response (CR). In addition, approximately 39% of patients developed stable disease (SD). This indicates that brigatinib has significant anti-tumor activity in the treatment of ALK-positive NSCLC.

2. Prolong survival: Clinical trials also show that brigatinib can significantly prolong the overall survival of patients with ALK-positive NSCLC. According to the study results, the median overall survival in the brigatinib group was less than two years, compared with less than one year in the chemotherapy group. This suggests that brigatinib can significantly improve patient survival.

3. Good tolerance: Brigatinib has shown good tolerance in clinical trials. Most patients tolerate brigatinib doses, and only a minority require dose reductions or treatment interruptions. Common adverse reactions include nausea, vomiting, fatigue, diarrhea, and headache, but most patients can alleviate these adverse reactions by adjusting the treatment plan or auxiliary drugs.

In summary, brigatinib, as a new type of ALK inhibitor, has significant efficacy and tolerability in the treatment of ALK-positive NSCLC. However, each patient's situation is different, so a doctor should be consulted before using brigatinib to determine the best treatment plan for each individual case.